ASP5736

ASP5736 is an experimental drug developed by Astellas Pharma, which acts as a selective antagonist for the serotonin receptor 5-HT5A, with significantly higher potency than the older drug SB-699,551. In animal studies, it was found to reduce drug appropriate responding produced by LSD, but not DOI, and has also been found to reduce the cognitive dysfunction and memory deficits produced by scopolamine in animal studies, which has been suggested may indicate a potential role for 5-HT5A antagonists in the treatment of schizophrenia, as well as other conditions such as fragile X syndrome.

References

Uses material from the Wikipedia article ASP5736, released under the CC BY-SA 4.0 license.